Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD 0.2900
-0.0200 (-6.45%)
Oct 19, 2026, 3:23 PM AEST
Alterity Therapeutics Stock Forecast
ASX-ATH's stock price has decreased by -51.67% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 analysts polled by S&P Global, Alterity Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.52. The average 1-year stock price forecast is 1,803.45% higher than the current stock price, while the lowest is $0.95 (+227.59%) and the highest is $10.00 (+3,348.28%).
Price Target: $5.52 (+1,803.45%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Aug 13, 2026.
Analyst Ratings
The average analyst rating for Alterity Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $0.95 | Buy | Maintains | $0.95 | +227.59% | Aug 13, 2026 |
Financial Forecast
Revenue This Year
1.02M
from 3.61M
Decreased by -71.72%
Revenue Next Year
1.84M
from 1.02M
Increased by 80.28%
EPS This Year
-0.10
from -0.11
EPS Next Year
-1.10
from -0.10
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.